Imugene Ltd has dosed the first patient in the BTKi combination cohort of its Phase 1b azer-cel study, expanding its clinical program into a global market worth about $12 billion by 2025. The patient, treated in Texas, has mantle cell lymphoma and had previously failed BTKi therapy. Azer-cel is an off-the-shelf allogeneic CAR T cell therapy aimed at advanced blood cancers with high unmet needs. This new cohort tests azer-cel combined with BTKi to evaluate safety and early efficacy in patients who relapsed after prior BTKi treatment, potentially broadening clinical applications and supporting future partnerships. The study is ongoing across 15 sites in the US and Australia, with updates expected as more data matures.
The US government is actively negotiating to take equity stakes in AI companies like OpenAI and Anthropic ahead of their planned IPOs, following a precedent set by its investment in Intel. This move aims to give the public a share in AI-driven growth...
Trulieve Cannabis Corp. made history by becoming the first U.S. cannabis company to list on the New York Stock Exchange under the ticker TRLV. This milestone was enabled by the Trump administration's reclassification of cannabis to Schedule III for m...
West Fraser Timber Co. Ltd. announced a quarterly dividend of US$0.32 per share on its Common and Class B Common shares. The dividend will be paid on July 13, 2026, to shareholders of record as of June 25, 2026. Shareholders have the option to receiv...
BIO-key International, a leader in biometric authentication, received a Nasdaq notice for failing to file its quarterly 10-Q report on time for Q1 2026. Nasdaq's notice indicates the company's compliance with listing rules is under review, and a hear...
Nyxoah SA has issued 55,232,558 new ordinary shares as part of a previously announced public offering, increasing the total number of shares with voting rights to 99,926,284. This move follows a private placement to qualified investors outside the U....
